Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide. Issue 5 (1st August 2003)

• Record Type: Journal Article
• Authors: Janssen, M. L.; Pels, W.; Massuger, L. F.; Oyen, W. J.; Boonstra, H.; Corstens, F. H.; Boerman, O. C.
• Is Part Of: International journal of gynecological cancer. Volume 13:Issue 5(2003)
• Page Start: 607
• Page End: 613
• Publication Date: 2003-08-01
• Subjects: HMFG1 -- MUC1 -- ovarian cancer -- radioimmunotherapy -- 90Yttrium; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-00009577-200309000-00006
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Despite debulking surgery and multidrug chemotherapy, advanced stage ovarian cancer has a high mortality rate. Radioimmunotherapy (RIT) is a treatment modality using specific, radiolabeled antibodies that guide cytotoxic radionuclides to cancer cells. In the present study, the therapeutic efficacy of RIT with murine monoclonal antibody HMFG1 labeled with three different beta-radiation emitting radionuclides ( 90 Yttrium, 186 Rhenium, and 131 Iodine) was assessed in athymic BALB/c mice with intraperitoneally growing NIH:OVCAR-3 ovarian carcinoma xenografts. Each of the three intraperitoneally administered radiolabeled antibody preparations ( 90 Y-HMFG1, 186 Re-HMFG1, and 131 I-HMFG1) caused a significant delay in ascites formation and mortality as compared to the control groups treated with 90 Y-labeled irrelevant antibody, nonradiolabeled HMFG1, or phosphate buffered saline. Intraperitoneally (ip) administered 90 Y-HMFG1 was shown to have a significantly higher abdominal retention as compared to the intraperitoneally administered irrelevant antibody 90 Y-G250. Furthermore, intraperitoneally administered 90 Y-HMFG1 more effectively inhibited tumor growth than intravenously administered 90Y-HMFG1. It was concluded that in intraperitoneally located malignant disease with ascitic cell clusters and tumor deposits, intraperitoneal administration of RIT seemed preferable as compared to intravenous administration. The choice of the most optimal radionuclide in intraperitoneally located malignancies needs further research, but could well depend on tumor characteristics such as the size of the tumor lesions.